Cargando…

Acalculous cholecystitis associated with levodopa-carbidopa intestinal infusion therapy: A case report

Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is one of the primary therapies for improving advanced Parkinson's disease symptoms. Placement of the jejunal catheter through the abdominal wall for drug administration requires a percutaneous interventional procedur...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Viviana, González-Ortega, Guillermo, Suárez, Antoni, Garrido, Alicia, Cámara, Ana, Compta, Yaroslau, Valldeoriola, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287348/
https://www.ncbi.nlm.nih.gov/pubmed/35856047
http://dx.doi.org/10.1016/j.prdoa.2022.100150
Descripción
Sumario:Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is one of the primary therapies for improving advanced Parkinson's disease symptoms. Placement of the jejunal catheter through the abdominal wall for drug administration requires a percutaneous interventional procedure called percutaneous endoscopic gastrostomy (PEG). PEG is considered a safe and straightforward procedure, and it is performed very commonly in clinical practice. In the context of LCIG treatment, severe adverse events have been identified, such as intestinal bleeding and acute abdomen [1], but acute acalculous cholecystitis (AAC) has never been reported.